PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS
May 1, 2004, 00:00
10.1016/S1098-3015(10)62150-X
https://www.valueinhealthjournal.com/article/S1098-3015(10)62150-X/fulltext
Title :
PCN8 OUTCOMES AND COSTS OF SURROGATE END-POINTS (SES) AND BIOMARKERS IN PHASE I ONCOLOGY CLINICAL TRIALS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)62150-X&doi=10.1016/S1098-3015(10)62150-X
First page :
Section Title :
Open access? :
No
Section Order :
88